A two-center comparison of the cardiovascular effects of cisatracurium (Nimbex) and vecuronium in patients with coronary artery disease.

@article{Konstadt1995ATC,
  title={A two-center comparison of the cardiovascular effects of cisatracurium (Nimbex) and vecuronium in patients with coronary artery disease.},
  author={Steven N. Konstadt and David L. Reich and Thomas Stanley and Marietta DePerio and Cynthia M. Chuey and Caryl Schwartzbach and M. B. Abou-donia},
  journal={Anesthesia and analgesia},
  year={1995},
  volume={81 5},
  pages={
          1010-4
        }
}
Cisatracurium (Nimbex) is an intermediate-acting benzylisoquinolinium neuromuscular blocker that is one of the stereoisomers of atracurium. It causes no clinically significant cardiovascular side effects or histamine release in doses up to 8 x ED95 in healthy patients. Seventy patients undergoing elective myocardial revascularization consented to participate in an Institutional Review Board approved pilot study (10 patients) and an open-label, randomized, controlled trial comparing the… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS

[Short acting muscle relaxants: is neuromuscular monitoring still necessary?].

  • Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS
  • 2009
VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Similar Papers